All In Biotech

Drug Trial Radar · NCT07652294

Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants With Inflammatory Bowel Disease

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

645

Planned (sponsor's estimate)

Start

Jun 8, 2026

Primary completion

Mar 2, 2029

Study completion Jan 3, 2030

Sponsor

Lead sponsor
Spyre Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, long-term extension (LTE) study in participants with ulcerative colitis (UC) from Study SPY123-201 (The SKYLINE-UC study).

Conditions

  • Ulcerative Colitis
  • Inflammatory Bowel Diseases
  • Colitis
  • Colitis, Ulcerative

Interventions

  • SPY001Drug

    Experimental

  • SPY002Drug

    Experimental

  • SPY003Drug

    Experimental

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who experienced an adverse eventTime frame: Week 96

Locations

100 sites in 24 countries. Site status is shown where the registry gives one.

  • Site 023

    La Jolla, California

  • Site 012

    Lancaster, California

  • Site 007

    Kissimmee, Florida

  • Site 035

    Marrero, Louisiana

  • Site 028

    Rochester, Minnesota

  • Site 025

    Providence, Rhode Island

  • Study Site 002

    San Antonio, Texas

  • Site 008

    Southlake, Texas

  • Site 019

    Tacoma, Washington

  • Site 102

    Lujan de Cuyo, Mendoza Province, Argentina

  • Site 103

    Rosario, Santa Fe Province, Argentina

  • Site 208

    Concord, New South Wales, Australia

  • Site 206

    South Brisbane, Queensland, Australia

  • Site 461

    Salzburg, Austria

  • Site 463

    Linz, Upper Austria, Austria

  • Site 473

    Leuven, Flemish Brabant, Belgium

  • Site 471

    Ghent, Oost-Vlaanderen, Belgium

  • Site 126

    Passo Fundo, Rio Grande Sul, Brazil

  • Site 128

    Santo André, São Paulo, Brazil

  • Site 153

    Osorno, Los Lagos Region, Chile

  • Site 152

    Santiago, Santiago Metropolitan, Chile

  • Site 531

    Brno, Czechia

  • Site 584

    Kutaisi, Georgia

  • Site 589

    Marneuli, Georgia

  • Site 581

    Tbilisi, Georgia

  • Site 588

    Tbilisi, Georgia

  • Site 583

    Tbilisi, Georgia

  • Site 586

    Tbilisi, Georgia

  • Site 582

    Tbilisi, Georgia

  • Site 587

    Tbilisi, Georgia

  • Site 603

    Ulm, Germany

  • Site 634

    Athens, Greece

  • Site 654

    Békéscsaba, Hungary

  • Site 651

    Budapest, Hungary

  • Site 652

    Székesfehérvár, Hungary

  • Site 673

    Legnano, Milan, Italy

  • Site 672

    Negrar, Verona, Italy

  • Site 424

    Amman, Jordan

  • Site 421

    Amman, Jordan

  • Site 422

    Irbid, Jordan

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.